Antidiabetic drug metformin (Glucophage R ) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription
Open Access
- 10 March 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 106 (10), 3907-3912
- https://doi.org/10.1073/pnas.0807991106
Abstract
Epidemiological, clinical and experimental evidence suggests a link between type 2 diabetes and Alzheimer's disease (AD). Insulin modulates metabolism of β-amyloid precursor protein (APP) in neurons, decreasing the intracellular accumulation of β-amyloid (Aβ) peptides, which are pivotal in AD pathogenesis. The present study investigates whether the widely prescribed insulin-sensitizing drug, metformin (GlucophageR), affects APP metabolism and Aβ generation in various cell models. We demonstrate that metformin, at doses that lead to activation of the AMP-activated protein kinase (AMPK), significantly increases the generation of both intracellular and extracellular Aβ species. Furthermore, the effect of metformin on Aβ generation is mediated by transcriptional up-regulation of β-secretase (BACE1), which results in an elevated protein level and increased enzymatic activity. Unlike insulin, metformin exerts no effect on Aβ degradation. In addition, we found that glucose deprivation and various tyrphostins, known inhibitors of insulin-like growth factors/insulin receptor tyrosine kinases, do not modulate the effect of metformin on Aβ. Finally, inhibition of AMP-activated protein kinase (AMPK) by the pharmacological inhibitor Compound C largely suppresses metformin's effect on Aβ generation and BACE1 transcription, suggesting an AMPK-dependent mechanism. Although insulin and metformin display opposing effects on Aβ generation, in combined use, metformin enhances insulin's effect in reducing Aβ levels. Our findings suggest a potentially harmful consequence of this widely prescribed antidiabetic drug when used as a monotherapy in elderly diabetic patients.This publication has 55 references indexed in Scilit:
- Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathologyNeurology, 2008
- Amyloid beta oligomers induce impairment of neuronal insulin receptorsThe FASEB Journal, 2007
- Metformin/rosiglitazone combination pill (Avandamet®) for the treatment of patients with Type 2 diabetesExpert Opinion on Pharmacotherapy, 2007
- The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s DiseaseExperimental Gerontology, 2007
- The Alzheimer's disease Beta-secretase enzyme, BACE1Molecular Neurodegeneration, 2007
- Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's diseaseThe Pharmacogenomics Journal, 2006
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001
- Cellular and molecular basis of b-amyloid precursor protein metabolism (Y2K update)Frontiers in Bioscience-Landmark, 2000
- The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's diseaseTrends in Cell Biology, 1998
- Brain insulin and insulin receptors in aging and sporadic Alzheimer's diseaseJournal of Neural Transmission, 1998